Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients: A naturalistic, open-label study

Maher Karam-Hage, Jason D. Robinson, Ashutosh Lodhi, Kirk J. Brower

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: We sought to determine whether sustained-release bupropion (bupropion-SR) reduces smoking and promotes smoking cessation among alcohol-dependent (AD) smokers while they are in early recovery from alcohol. Methods: We conducted an open-label, naturalistic study among AD smokers enrolled in an outpatient treatment program. The treatment group (n=58) was offered bupropion-SR and brief smoking cessation counseling. A control group (n=57) was matched to the treatment group by age, sex, ethnicity, cigarette use, and years of alcohol dependence. The controls received no smoking cessation intervention. We collected tobacco and alcohol abstinence data for 6 months after enrollment. Results: Participants in the treatment group were more likely to abstain from smoking than controls, at any of the followup time points. The treatment group smoked less cigarettes per day (CPD) at baseline, 30 days and 180 days post-baseline, compared to controls. These findings persisted after adjusting for possible covariates. Conclusion: Bupropion-SR may be helpful to quit or reduce smoking for recently abstinent AD individuals.

Original languageEnglish (US)
Pages (from-to)123-129
Number of pages7
JournalCurrent Clinical Pharmacology
Volume9
Issue number2
DOIs
StatePublished - 2014

Keywords

  • Alcohol dependence
  • Bupropion
  • Cessation
  • Nicotine
  • Smoking
  • Treatment

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients: A naturalistic, open-label study'. Together they form a unique fingerprint.

Cite this